Endpoints Slack interview: Zetta’s Dylan Reid on AI biotech investingnews2025-08-13T14:00:47+00:00August 13th, 2025|Endpoints News|
VC firm Hatteras closes $200M for life sciences as it reaches 100th investmentnews2025-08-13T12:00:18+00:00August 13th, 2025|Endpoints News|
Autolus says it won’t make money from its cell therapy in Europe until 2027news2025-08-13T11:17:42+00:00August 13th, 2025|Endpoints News|
US tariffs could undo generic drugmakers’ efforts to be less reliant on Chinese raw materials, experts saynews2025-08-13T11:00:20+00:00August 13th, 2025|Endpoints News|
Treg biotech Abata Therapeutics closes as money runs shortnews2025-08-13T03:18:44+00:00August 13th, 2025|Endpoints News|
AbbVie announces $195M API plant outside of Chicagonews2025-08-12T19:39:20+00:00August 12th, 2025|Endpoints News|
Summit, the hottest PD-1xVEGF biotech, is burning cash fast — but it may not be cause for alarmnews2025-08-12T19:37:28+00:00August 12th, 2025|Endpoints News|
Padcev-Keytruda combo shows ‘compelling’ survival results in bladder cancernews2025-08-12T18:42:04+00:00August 12th, 2025|Endpoints News|
Fertility startup Gameto raises $44M to fund Phase 3 study of stem cell IVF therapynews2025-08-12T18:02:55+00:00August 12th, 2025|Endpoints News|
Insmed gets FDA approval for the first DPP1 inhibitor, in lung diseasenews2025-08-12T17:01:25+00:00August 12th, 2025|Endpoints News|
